A new synthetic phage platform is being developed, which could potentially reshape antimicrobial therapy. The platform involves engineering bacteriophages, or viruses that infect bacteria, to target specific bacteria such as Pseudomonas aeruginosa. The development of this technology is part of a broader effort to address antibiotic resistance, although its current status and potential applications are still emerging.